EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
about
The Treatment of Cushing's Disease.Effects of Carbenoxolone on the Canine Pituitary-Adrenal AxisTreatment of pituitary carcinomas and atypical pituitary adenomas: a reviewTemozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations.Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Update on medical treatment for Cushing's disease.Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's diseaseVandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic miceRecurrent gain-of-function USP8 mutations in Cushing's disease.Pituitary tumors.Cushing's syndrome: epidemiology and developments in disease management.Cushing's disease: towards precision medicine.The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to EctopicsLack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary AdenomasPituitary Medicine From Discovery to Patient-Focused Outcomes.Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapyThe genome-wide mutational landscape of pituitary adenomas.Recent advances in the medical treatment of Cushing's disease.Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomasSca1⁺ murine pituitary adenoma cells show tumor-growth advantage.Recent developments in drug therapy for Cushing's disease.Molecular basis of pharmacological therapy in Cushing's disease.Aggressive pituitary adenomas--diagnosis and emerging treatments.Pituitary side effects of old and new drugs.The role of genetic and epigenetic changes in pituitary tumorigenesis.New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.Cushing's syndrome: an update on current pharmacotherapy and future directions.USP8: a novel therapeutic target for Cushing's disease.Genetics of Cushing's disease: an update.Endocrinology research-reflecting on the past decade and looking to the next.POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease.
P2860
Q27010590-85401C12-8639-4870-917D-B4330DB7C88FQ28547156-7ABFC8B3-DC7A-4C75-8304-318B03EFD3F9Q30872897-248EBDEF-E44B-4786-B216-A6C078318DCBQ33427688-7E9A3EE7-899F-4596-A443-4D0E8C0E5376Q33570330-99F9B669-A22F-4C04-AFE1-89EACAEF0B05Q33632000-885F2317-5997-4277-A80B-0654D30EBCF7Q33680681-2E037471-C636-4FE9-A0DF-720BED7DEBA3Q33802284-03239CD8-337D-4841-BE16-B1E6D9A8E19AQ33904619-2A29E35D-B703-417B-BB52-E5B49A873753Q34131012-8C1B58C2-791D-4C85-AE24-2850826B2BC1Q34240076-179D6131-FC91-4ACC-8D29-5A154BBC0E30Q34745279-976BD5D9-7362-41FC-8C14-777B87F01CE0Q35146226-FF63D444-DB20-4B3C-B320-DE0274B2891BQ35154035-62631492-D64A-4BB0-89F0-B8DCBC7878E2Q35531889-962A7877-153F-43D9-A6AC-F247FA1CB3CFQ35686067-041058E8-1A49-4A78-82EA-02E37ECFB676Q35813265-88A735AD-CF18-4DF4-AAD5-CBF3B785F1EAQ36184067-E2007766-6ADB-4A5B-998A-A0E5BBDF98E2Q36231629-74A48590-04CE-45BA-ADE9-A46AF65B5C4FQ36716025-DE0359A6-CD49-4711-9A7E-CBCFB83177F6Q36724063-8B27AA6F-52B1-4310-9D28-B43AD8427482Q37049132-C476934D-4D61-48A5-B6E7-35BBDB5725F0Q37400088-F4D096F2-ED85-4A90-8545-846D408C02FFQ37621524-5133AB06-0F4E-4380-AED3-9A00C457992AQ37651359-6F2BF2B9-9767-4F22-8C39-46CA35A4FB6FQ37690499-58DBBAF7-4ACC-4A00-A539-629E7A8C11C0Q38112082-441A9F70-81D6-43F4-AB4E-CEA5A195A1F2Q38165863-5F79F52D-703F-403A-97ED-38A84FC01870Q38211375-020EC464-B521-459C-81BE-D4979FAA447FQ38234756-2D79A3D0-6E43-4743-864C-78AA50A43595Q38274982-8CFD1BA7-0C3A-40BA-BE5B-9172089FD949Q38328843-78226446-1F3B-4E4F-B067-0EBBF5B9D455Q38541695-396FED4E-AA59-4D24-8405-B8F65AF60497Q38545050-E713B2C1-5360-4635-80D0-476E46625D4FQ38553643-AAD863F7-1B93-4BAE-A077-DFE58FCA25BAQ38605678-7B5C20D7-425B-41EE-A6EF-CEAEDE278CDBQ38715916-94F7E885-710B-4EA7-B492-81A2E5F7F138Q38755339-3D72515F-825A-48BF-9BDD-064F6EA86C0BQ38777251-FCE7A4CB-1255-4006-9DF0-92A72B125619Q38785782-235FC317-6F08-48B4-ADE5-FDABF5C72870
P2860
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@ast
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@en
type
label
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@ast
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@en
prefLabel
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@ast
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@en
P2093
P2860
P356
P1476
EGFR as a therapeutic target f ...... -secreting pituitary adenomas.
@en
P2093
Adam Mamelak
Anat Ben-Shlomo
Dave Bruyette
Hidenori Fukuoka
Shlomo Melmed
Song-Guang Ren
P2860
P304
P356
10.1172/JCI60417
P407
P577
2011-11-21T00:00:00Z